

ARTICOLI PUBBLICATI SU RIVISTE SCIENTIFICHE	Impact Factor 2022/2023
1. Inno A , Peri M, Turazza M , Bogina G, Modena A , Massocco A, Pezzella M, Valerio M , Mazzola R, Olivari L, Severi F, Foti G, Mazzi C, Marchetti F, Lunardi G, Salgarello M, Russo A, Gori S . The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy. <i>Front Oncol.</i> 2022;12:976823.	4,7
2. Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S , D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. <i>Future Oncol.</i> 2022 Dec;18(40):4457–64.	3,3
3. Bisceglia I, Canale ML, Silvestris N, Gallucci G, Camerini A, Inno A , Camilli M, Turazza FM, Russo G, Paccone A, Mistrulli R, De Luca L, Di Fusco SA, Tarantini L, Lucà F, Oliva S, Moreo A, Maurea N, Quagliariello V, Ricciardi GR, Lestuzzi C, Fiscella D, Parrini I, Racanelli V, Russo A, Incorvaia L, Calabrò F, Curigliano G, Cinieri S, Gulizia MM, Gabrielli D, Oliva F, Colivicchi F. Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals. <i>Front Cardiovasc Med.</i> 2023;10:1223660.	3,6
4. Inno A , Bogina G, Settanni G, Salgarello M, Foti G, Pomari C, Picece V , Gori S . First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression. <i>Drug Target Insights.</i> 2023;17:110–3.	2,7
5. Inno A , Lattuada E, Foti G, Gori S . Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report. <i>Front Oncol.</i> 2023;13:1053497.	4,7
6. Inno A , Marchetti F, Valerio M , Gaj Levra N, Alongi F, Foti G, Gori S . Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report. <i>Drug Target Insights.</i> 2023;17:90–1.	2,7
7. Piubelli C, Valerio M , Verzè M, Nicolis F, Mantoan C, Zamboni S , Perandin F, Rizzi E, Tais S, Degani M, Caldrea S, Gobbi FG, Bisoffi Z, Gori S . Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments. <i>Front Oncol.</i> 2023;13:1089944.	4,7
8. Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F, Italian Liver Cancer (ITA.LI.CA) group . Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. <i>Gut.</i> 2023 Jan;72(1):141–52.	24,5
9. Inno A , Peri M, Turazza M , Bogina G, Modena A , Massocco A, Pezzella M, Valerio M , Mazzola R, Olivari L, Severi F, Foti G, Mazzi C, Marchetti F, Lunardi G, Salgarello M, Russo A, Gori S . The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy. <i>Front Oncol.</i> 2023 Jan 4;12:976823.	4,7
10. Tralongo P, Cappuccio F, Gori S , Donato V, Beretta G, Elia A, Romano F, Iacono M, Tralongo AC, Bordonaro S, Di Mari A, Giuliano SR, Buccafusca G, Careri MC, Santoro A. Clinicians' and Patients' Perceptions and Use of the Word 'Cured' in Cancer Care: An Italian Survey. <i>Curr Oncol.</i> 2023 Jan 17;30(2):1332–53.	2,6
11. Quagliariello V, Bisceglia I, Berretta M, Iovine M, Canale ML, Maurea C, Giordano V, Paccone A, Inno A , Maurea N. PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint	5,2

Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology. Cancers (Basel). 2023 Feb 22;15(5):1397.	
12. Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churrua Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A, INOVATYON study group . INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. Br J Cancer. 2023 Apr;128(8):1503–13.	8,8
13. Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentiis M, Fabi A, Rimanti A, Michelotti A, Mansutti M, Russo A, Montemurro F, Frassoldati A, Durando A, Gori S , Turletti A, Tamberi S, Urracci Y, Fregatti P, Razeti MG, Caputo R, De Angelis C, Sanna V, Gasparini E, Agostinetto E, de Azambuja E, Poggio F, Boni L, Del Mastro L. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies. eClinicalMedicine. 2023 May 1;59:101931.	15,1
14. Gori S, Modena A , Foglietta J, Verzè M, Inno A , Casarin A, Russo A, Nicolis F. Adherence to oral hormonal anticancer agents in breast cancer. Tumori. 2023 Jun;109(3):262–8.	1,707
15. Muscaritoli M, Modena A, Valerio M , Marchetti P, Magarotto R , Quadrini S, Narducci F, Tonini G, Grassani T, Cavanna L, Di Nunzio C, Citterio C, Occelli M, Strippoli A, Chiurazzi B, Frassoldati A, Altavilla G, Lucenti A, Nicolis F, Gori S . The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study. Cancers (Basel). 2023 Jun 15;15(12):3206.	5,2
16. Inno A , Bogina G, Settanni G, Foti G, Tessari R, Gori S . Mucoepidermoid Carcinoma of the Lung Harboring MET Exon 14 Skipping Mutation Treated With Tepotinib: A Case Report. JCO Precis Oncol. 2023 Jul;7:e2300136.	4,6
17. Inno A , Tarantini L, Parrini I, Spallarossa P, Maurea N, Bisceglia I, Silvestris N, Russo A, Gori S . Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. Curr Oncol Rep. 2023 Jul;25(7):743–51.	2,6
18. Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A , Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer. Clin Cancer Res. 2023 Jul 14;29(14):2714–24.	11,5
19. Renzelli V, Gallo M, Morviducci L, Marino G, Ragni A, Tuveri E, Faggiano A, Mazzilli R, Natalicchio A, Zatelli MC, Montagnani M, Fogli S, Giuffrida D, Argentiero A, Danesi R, D'Oronzo S, Gori S , Franchina T, Russo A, Monami M, Sciacca L, Cinieri S, Colao A, Avogaro A, Di Cianni G, Giorgino F, Silvestris N. Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer. Cancers (Basel). 2023 Aug 24;15(17):4237.	5,2
20. Gori S , Fabi A, Angiolini C, Turazza M , Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Frassoldati A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M , Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Nicolis F. Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of	5,2

a Prospective Observational Multicenter BRIDE Study. Cancers (Basel). 2023 Oct 4;15(19):4852.	
21. Inno A, Picece V, Bogina G, Settanni G, Viassolo V, Salgarello M, Gori S . Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report. Clinical Lung Cancer [Internet]. 2023 Oct 29 [cited 2024 Jan 9]; Available from: https://www.sciencedirect.com/science/article/pii/S1525730423002255	3,6
22. Metro G, Gariazzo E, Costabile S, Baglivo S, Roila F, Colamartini F, Palumbo B, Chiarini P, Gori S , Conti A, Marcomignin L, Bellezza G, Lunardi G. Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer. Oncol Ther. 2023 Nov 16;	2,7
23. Pellegrino B, Tommasi C, Serra O, Gori S , Cretella E, Ambroggi M, Frassoldati A, Bisagni G, Casarini C, Bria E, Carbognin L, Fiorio E, Mura A, Zamagni C, Gianni L, Zambelli A, Montemurro F, Tognetto M, Todeschini R, Missale G, Campanini N, Silini EM, Maglietta G, Musolino A. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016). J Immunother Cancer. 2023 Nov 28;11(11):e007667.	10,9
24. Pelizzaro F, Trevisani F, Simeon V, Vitale A, Cillo U, Piscaglia F, Missale G, Sangiovanni A, Foschi FG, Cabibbo G, Caturelli E, Di Marco M, Azzaroli F, Brunetto MR, Raimondo G, Vidili G, Guarino M, Gasbarrini A, Campani C, Svegliati-Baroni G, Giannini EG, Mega A, Masotto A, Rapaccini GL, Magalotti D, Sacco R, Nardone G, Farinati F, Italian Liver Cancer (ITA.LI.CA) group . Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023 Dec;43(12):2762–75.	6,7
25. Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F, GONO Foundation Investigators . Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. J Clin Oncol. 2023 Dec 1;41(34):5263–73.	45,4
26. Ceccaroni M, Roviglione G, Bruni F, Dababou S, Venier M, Zorzi C, Salgarello M, Ruffo G, Alongi F, Gori S , Driul L, Uccella S, Barra F. 'Things Have Changed'-Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients. Cancers (Basel). 2023 Dec 6;15(24):5726.	5,2
27. Conte B, Boni L, Bisagni G, Durando A, Sanna G, Gori S , Garrone O, Tamberi S, De Placido S, Schettini F, Pazzola A, Ponzzone R, Montemurro F, Lunardi G, Notaro R, De Angioletti M, Turletti A, Mansutti M, Puglisi F, Frassoldati A, Porpiglia M, Fabi A, Generali D, Scognamiglio G, Rossi M, Brasó-Maristany F, Prat A, Cardinali B, Piccioli P, Serra M, Lastraioli S, Bighin C, Poggio F, Lambertini M, Del Mastro L. SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials. Clin Cancer Res. 2023 Dec 15;29(24):5217–26.	11,5
TOTALE IF	209,307